SEC Form 4 · accession 0000899243-18-007985

Arcus Biosciences, Inc. · RCUS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Mar 19, 2018

Accepted (ET)

Mar 19, 2018 · 5:23 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001724521

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Mar 19, 2018	C	2,475,654	—	A	3,818,078	I	By Trust
Common Stock^F3	Mar 19, 2018	P	66,666	$15.00	A	3,884,744	I	By Trust
Common Stock^F4	holding	—	—		—	189,393	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Convertible Preferred Stock^F2	—	Mar 19, 2018	C	2,267,676	D	—	—	Common Stock	2,267,676	I
Series B Convertible Preferred Stock^F2	—	Mar 19, 2018	C	125,012	D	—	—	Common Stock	125,012	I
Series C Convertible Preferred Stock^F2,F5	—	Mar 19, 2018	C	82,966	D	—	—	Common Stock	82,966	I

F1The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock.
F2The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
F3Represents shares purchased in the Issuer's initial public offering.
F4The total includes 126,262 shares of Common Stock acquired by the Reporting Person on January 12, 2018 for $5.39 per share pursuant to the exercise of an option granted on January 4, 2018.
F5Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for $11.6915 per share.